Biotech, Food, Drug

The food we eat and the medicine we put into our bodies are highly regulated by a variety of government agencies. In the United States by the Food and Drug Administration (FDA) and the United States Department of Agriculture (USDA) regulate the processes by which food makes its way to the grocery store and medicine is approved for consumer use.  As the science grows more complex behind the pharmaceutical and food industry, interpretation of the regulations in place is becoming more nuanced.  Overseas, these industries are regulated by a variety of agencies; for example, the Minister of Agriculture in Canada, Centre for Food Safety in Hong Kong, and the Committee of Environmental, Public Health and Food Safety (EU), are among the many governing-bodies which regulate biotechnology, food, and drugs throughout the world.

The National Law Review is your free online resource to agency news, emerging topics in food and drug, and the latest in biotechnology updates. From nanotechnologies being used in research, to regulations of imported foods coming into the US from overseas or the development of medical devices and drugs, readers can find expert legal analysis of the developments in the industry, as well as reports on changes within the agencies that regulate these industries. The National Law Review also covers topics related to licensing, Food Safety and Inspection Services (FSIS), food and beverage regulation in the US and worldwide, nutrition labeling, and country of origin labeling guidelines.

With recent legislation being passed throughout the US in relation to marijuana use, both for recreational and medicinal purposes, readers will also find up-to-date information, litigation, and news coming from this area of interest as well. Regulations in California for labeling and proper sales of marijuana, to use in different states, or internationally, as well as rules for promoting and advertising marijuana are also covered on the site. Additionally, the development and changing landscape of tobacco use to include vaping, and how e-cigarettes and vaping are regulated, is also covered by NLR authors.

Readers who are interested in food safety, inspection, imports into the US, and regulations, these topics are covered regularly on The National Law Review as well. New legislation from the FDA, USDA, Department of Agriculture, and international bodies, are covered on the site. If you are looking for details on new nutrition-labeling regulations or health risks of consuming certain imported foods, you will find these topics, and many more, on The National Law Review.

For hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis Twitter feed, and sign up for complimentary e-news bulletins.

Custom text Title Organization Sort descending
Jun
4
2023
FDA Cracking Down on Unapproved HCT/Ps with Fourth Untitled Letter of 2023 Sheppard, Mullin, Richter & Hampton LLP
Jun
11
2023
Is this “Good-Bye” to the Two-Year Mandatory Minimum in Healthcare Fraud Cases? Sheppard, Mullin, Richter & Hampton LLP
Jun
14
2023
Healthier Choices Management Corp. v. Philip Morris USA, Inc. No. 22-1268 (Fed. Cir. Apr. 12, 2023) Sheppard, Mullin, Richter & Hampton LLP
Apr
15
2020
FCPA Landmines Beneath the Surface of the COVID-19 Crisis - May 6 Sheppard, Mullin, Richter & Hampton LLP
Aug
17
2023
Fifth Circuit Rules to Reinstate Abortion Pill Restrictions Sheppard, Mullin, Richter & Hampton LLP
May
5
2020
IP Protection and the Open COVID Cure Chase Sheppard, Mullin, Richter & Hampton LLP
Oct
9
2023
At HLTH 2023: General Catalyst’s HATCo Introduces a Radically Ambitious and Transformative Model for Healthcare Sheppard, Mullin, Richter & Hampton LLP
Jan
2
2024
The Intertwining Nature of Motivation to Combine and Reasonable Expectation of Success Sheppard, Mullin, Richter & Hampton LLP
Jan
29
2024
2024 Top-of-Mind Issues for Life Sciences Companies Sheppard, Mullin, Richter & Hampton LLP
Feb
6
2024
FDA’s Office of Prescription Drug Promotion Issues Its First Untitled Letter of the Year to Novartis for Misleading Statement Relating to KISQALI® Sheppard, Mullin, Richter & Hampton LLP
Oct
20
2020
California Governor Pulls the Plug on Genetic Information Privacy Act Sheppard, Mullin, Richter & Hampton LLP
Feb
20
2024
New Bills Being Served Up That May Soon Impact Food Retailers and Manufacturers Sheppard, Mullin, Richter & Hampton LLP
Mar
19
2024
Time to Refresh? FDA Issues Draft Guidance on Key Information and Informed Consent Sheppard, Mullin, Richter & Hampton LLP
Mar
29
2021
FDA Announces First Ever Facility Fees for OTC Drug Manufacturers Sheppard, Mullin, Richter & Hampton LLP
Apr
15
2021
Breaking Down FDA’s New Remote Monitoring Strategy Sheppard, Mullin, Richter & Hampton LLP
Jun
23
2013
Federal Trade Commission (FTC) v. Actavis: What Does It Mean for Reverse-Payment Settlements? Sheppard, Mullin, Richter & Hampton LLP
Jul
4
2013
European Union (EU) Carbon Trading System Wins Parliament's Support Sheppard, Mullin, Richter & Hampton LLP
Jun
26
2018
Ninth Circuit Confirms that Class Action Plaintiffs Must Plausibly Establish Future Intent To Re-Purchase To Maintain Claims for Injunctive Relief Sheppard, Mullin, Richter & Hampton LLP
Feb
14
2019
HIMMS19 Conference – Blockchain Symposium Recap Sheppard, Mullin, Richter & Hampton LLP
Mar
29
2019
OH SNAP! Supreme Court to Take on Meaning of Key FOIA Exemption Sheppard, Mullin, Richter & Hampton LLP
Nov
11
2014
Amgen/Sandoz Disputes Will Clarify BPCIA (Biologics Price Competition and Innovation Act) Issues Sheppard, Mullin, Richter & Hampton LLP
Dec
10
2014
Dole Defeats “All Natural Claims” for Sweet Victory Sheppard, Mullin, Richter & Hampton LLP
Aug
25
2022
Healthcare Reforms Under the IRA: Expanding Access to Care Sheppard, Mullin, Richter & Hampton LLP
Jan
7
2020
FDA Year in Review: A Shifting Regulatory Landscape Sheppard, Mullin, Richter & Hampton LLP
Mar
20
2023
FDA Draft Guidance Signifies Acceptance of the Term “Milk” to Describe Plant-Based Alternatives Sheppard, Mullin, Richter & Hampton LLP
Mar
5
2020
Nota Bene Episode 71: Shifting Regulatory Landscapes at the FDA: Cannabis, Vaping and Intelligent Medical Devices with Allison Fulton [PODCAST] Sheppard, Mullin, Richter & Hampton LLP
Mar
10
2020
Prop 65 Warnings and Acrylamide in Food – Can I Still Have My Coffee and Drink it Too? Sheppard, Mullin, Richter & Hampton LLP
Mar
16
2020
FDA Grants COVID-19 Diagnostic Emergency Use Authorizations, And Other Recent FDA Actions With to Address COVID-19 Sheppard, Mullin, Richter & Hampton LLP
Apr
1
2020
Gifting Goods & Services to the U.S. Government in the Wake of the Coronavirus Outbreak Sheppard, Mullin, Richter & Hampton LLP
Jul
17
2020
Clearing the Air: FinCEN Guidance May Help Banks Find Their Way in the Field of Hemp Financing Sheppard, Mullin, Richter & Hampton LLP
Jan
21
2024
FDA Issues Final Rule and Guidance on Direct-To-Consumer Prescription Drug Advertisements Sheppard, Mullin, Richter & Hampton LLP
Mar
9
2024
Oregon Prescription Drug Price Transparency Act in Limbo Sheppard, Mullin, Richter & Hampton LLP
Jan
12
2021
FDA’s Action Plan for Artificial Intelligence: Highlights and Insights for Developers Sheppard, Mullin, Richter & Hampton LLP
Mar
8
2021
California Legislative Update: Employment-Related Bills on the Horizon Sheppard, Mullin, Richter & Hampton LLP
Nov
16
2010
Proposition 23's Failure Means Full Speed Ahead on AB 32 Sheppard, Mullin, Richter & Hampton LLP
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins